Neuphoria Therapeutics Files 8-K
Ticker: NEUP · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1191070
| Field | Detail |
|---|---|
| Company | Neuphoria Therapeutics Inc. (NEUP) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, other-event
TL;DR
Neuphoria filed an 8-K for an 'other event' on Jan 10th - details TBD.
AI Summary
Neuphoria Therapeutics Inc. filed an 8-K on January 14, 2025, reporting an "Other Event" that occurred on January 10, 2025. The filing does not provide specific details about the event itself, only that it is being reported under Item 8.01.
Why It Matters
This filing indicates a material event has occurred for Neuphoria Therapeutics, requiring disclosure to investors. However, the lack of detail means the specific impact remains unknown.
Risk Assessment
Risk Level: medium — The filing is an 8-K for an 'Other Event' without specific details, creating uncertainty about the nature and impact of the event.
Key Players & Entities
- Neuphoria Therapeutics Inc. (company) — Registrant
- January 10, 2025 (date) — Date of earliest event reported
- January 14, 2025 (date) — Date of report
- 100 Summit Dr, Burlington, Massachusetts 01803 (address) — Principal Executive Offices
- 781-439-5551 (phone_number) — Registrant's Telephone Number
FAQ
What specific event is Neuphoria Therapeutics Inc. reporting?
The filing states it is an 'Other Event' under Item 8.01, but does not provide specific details about the nature of the event.
When did the reported event occur?
The earliest event reported occurred on January 10, 2025.
When was this 8-K filing submitted?
The filing was submitted on January 14, 2025.
What is the principal business address of Neuphoria Therapeutics Inc.?
The principal executive offices are located at 100 Summit Dr, Burlington, Massachusetts 01803.
What is the telephone number for Neuphoria Therapeutics Inc.?
The registrant's telephone number is +1 781 439 5551.
Filing Stats: 731 words · 3 min read · ~2 pages · Grade level 14.3 · Accepted 2025-01-14 17:28:58
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share NEUP The Nasdaq
- $1.00 — 's common stock (the "Common Stock") of $1.00 or greater per share for 10 consecutive
Filing Documents
- ea0227706-8k_neupho.htm (8-K) — 27KB
- 0001213900-25-003492.txt ( ) — 197KB
- neup-20250110.xsd (EX-101.SCH) — 3KB
- neup-20250110_lab.xml (EX-101.LAB) — 33KB
- neup-20250110_pre.xml (EX-101.PRE) — 22KB
- ea0227706-8k_neupho_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On January 10, 2025, Neuphoria Therapeutics Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement") by maintaining a minimum closing bid price of the Company's common stock (the "Common Stock") of $1.00 or greater per share for 10 consecutive business days, from December 24, 2024 through January 8, 2025, and that the Minimum Bid Price Requirement matter is now closed. As previously disclosed in the Company's Current Report on Form 8-K filed on July 16, 2024, the Company had received a deficiency letter from Nasdaq indicating that the Company was not in compliance with the Minimum Bid Price Requirement because, for a period of 30 consecutive business days, the American Depositary Shares (the Company's then Nasdaq trading security prior to its completed re-domiciliation from Australia to Delaware (U.S.) effective December 24, 2024), failed to maintain a minimum bid price of $1.00 per share. That July 2024 letter provided the Company with a period of 180 calendar days, or until January 7, 2025, in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). As noted above, the Company has fully regained compliance with the applicable Nasdaq Listing Rule and the matter is now closed.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. These forward-looking statements and factors that may cause such differences include, without limitation, the ability of the Company to maintain the listing of its securities on Nasdaq and the risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 14, 2025 Neuphoria Therapeutics Inc. /s/ Spyridon Papapetropoulos Spyridon Papapetropoulos Chief Executive Officer and President 2